<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042872</url>
  </required_header>
  <id_info>
    <org_study_id>5481-03-0013</org_study_id>
    <secondary_id>R-454-03</secondary_id>
    <nct_id>NCT02042872</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid Administration in Acute Spinal Cord Injury</brief_title>
  <official_title>The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James J. Peters Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kessler Institute for Rehabilitation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>James J. Peters Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on
      preservation of regional and total skeletal mass (DXA).

      Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI,
      as evidenced by serial densitometry determinations (DXA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immobilization is associated with disuse osteoporosis. Spinal cord injury (SCI) produces a
      syndrome of acute skeletal immobilization with immediate and irreversible unloading of the
      involved skeletal regions resulting in accelerated bone loss. In addition to rapid bone loss,
      there are also the complications of hypercalciuria, hypercalcemia, nephrolithiasis, and renal
      insufficiency. In some reports, as much as 50% of regional bone mass has been lost within the
      first year after paralysis. A depletion of regional bone of such magnitude greatly increases
      the risk of fractures, with associated morbidity and increased cost of care. Often, these
      fractures occur with minimal or non-obvious trauma and may pass undiagnosed for varying
      lengths of time due to the absence of pain sensation. The acute complications of fracture may
      include hemorrhage, deep venous thrombosis, and autonomic dysreflexia. Long-term
      complications include functional deformity, non-union, infection, heterotopic calcification,
      and significantly longer healing time. The sociology-economic consequences include a minimum
      of 1 to 2 weeks of hospitalization and the potential need for an increased level of attendant
      care. This study will address the efficacy of a bisphosphonate, zoledronic acid (Reclast: 5
      mg; Novartis Pharmaceuticals Inc., East Hanover, NJ), in the prevention of the bone loss
      associated with acute SCI.

      Prevention of regional osteoporosis in persons with SCI would reduce the morbidity associated
      with fractures, a known secondary complication of immobilization. Thus, the quality of life
      would be improved in terms of employment responsibilities (reduction in days absent from
      employment and income lost) and personal activities (recreational endeavors, independence,
      and ease in which one performs activities of daily living). Individuals with SCI may then
      engage more securely in activities without fear of fracture, a tremendous psychological
      benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the distal femur and proximal tibia by using a customized research software program supplied by the manufacturer. This measurement will be the primary determinant (dependent measure) of difference among the treatment and control groups, and they will be followed over time at the previously specified time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) at the Total Hip at Baseline and Month 12</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the total hip.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Disuse Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <other_name>Zometa</other_name>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Within 3 months of the date of acute SCI.

          2. Motor-complete and incomplete SCI [American Spinal Injury Association Impairment Scale
             (AIS) of sensorimotor impairment (AIS A, B, and C)]

        Exclusion Criteria:

          1. Extensive life-threatening injuries (in addition to SCI)

          2. Femur or tibia fracture or extensive bone trauma

          3. History of prior bone disease (Paget's disease, overactive parathyroid, osteoporosis)

          4. Post-menopausal women

          5. Known allergy to bisphosphonates

          6. Severe underlying chronic illness

          7. Current diagnosis of cancer or history of cancer

          8. I am currently receiving corticosteroids

          9. Pregnancy or lactation

         10. I have been diagnosed with kidney problems

         11. As determined from the prescreening blood tests by the study physician Serum
             creatinine &gt; 2.0 mg/dl

         12. As determined from the prescreening blood tests by the study physician Corrected
             calcium &lt; 8 mg/dl or &gt; 11 mg/dl

         13. As determined from the prescreening blood tests by the study physician Elevated liver
             function enzymes &gt; 2 x upper limit of normal (ULN)

         14. I am taking a bisphosphonate for heterotopic ossification (HO) (an overgrowth of bone
             typically diagnosed shortly after SCI in the pelvic region)

         15. I have an existing dental condition or dental infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A Bauman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>James J. Peters VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kessler Institute for Rehabilitation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, Caminis J. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007 May;80(5):316-22. Epub 2007 Apr 7.</citation>
    <PMID>17417700</PMID>
  </reference>
  <reference>
    <citation>Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int. 2011 Jan;22(1):271-9. doi: 10.1007/s00198-010-1221-6. Epub 2010 Apr 1.</citation>
    <PMID>20358358</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>March 12, 2014</results_first_submitted>
  <results_first_submitted_qc>July 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2014</results_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>James J. Peters Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>William A. Bauman, M.D.</investigator_full_name>
    <investigator_title>Director VA RR&amp;D Center of Excellence for the Medical Consequences of SCI</investigator_title>
  </responsible_party>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Disuse Osteoporosis</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>Dual Energy X-ray Absorptiometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zoledronic Acid</title>
          <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoledronic Acid</title>
          <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Subject self reported date of birth used to calculate age</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="9.6"/>
                    <measurement group_id="B2" value="33.0" spread="11.0"/>
                    <measurement group_id="B3" value="29.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12.</title>
        <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the distal femur and proximal tibia by using a customized research software program supplied by the manufacturer. This measurement will be the primary determinant (dependent measure) of difference among the treatment and control groups, and they will be followed over time at the previously specified time points.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12.</title>
          <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the distal femur and proximal tibia by using a customized research software program supplied by the manufacturer. This measurement will be the primary determinant (dependent measure) of difference among the treatment and control groups, and they will be followed over time at the previously specified time points.</description>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Distal Femur</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.102" spread="0.148"/>
                    <measurement group_id="O2" value="1.134" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Distal Femur</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" spread="0.128"/>
                    <measurement group_id="O2" value="1.038" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Proximal Tibia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.274" spread="0.245"/>
                    <measurement group_id="O2" value="1.341" spread="1.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Proximal Tibia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.022" spread="0.267"/>
                    <measurement group_id="O2" value="1.237" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density (BMD) at the Total Hip at Baseline and Month 12</title>
        <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the total hip.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zoledronic Acid</title>
            <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) at the Total Hip at Baseline and Month 12</title>
          <description>An imaging method known as dual energy x-ray absorptiometry (DXA) was used to obtain BMD of the total hip.</description>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Total Hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.125" spread="0.166"/>
                    <measurement group_id="O2" value="1.020" spread="0.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Total Hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.042" spread="0.168"/>
                    <measurement group_id="O2" value="0.814" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Monthly assessment of medical history over the 24 month follow-up period after baseline assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zoledronic Acid</title>
          <description>At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Venous Thrombosis</sub_title>
                <description>Patient was admitted to hospital for lower extremity pain that was diagnosed as a deep venous thrombosis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Impaction</sub_title>
                <description>One participant was admitted to an acute care facility for bowel impaction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal headache</sub_title>
                <description>One participant was admitted to the hospital for severe migraine headaches. This was the result of leaking cerebral spinal fluid when spinal anesthesia punctured the dura mater during a Botulinum toxin procedure.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Two participants were admitted to an acute care facility for sever pain that after a complete work up was diagnosed as a urinary tract infection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <description>One participant was admitted to an acute care facility for symptoms resulting from a stage IV decubitus ulcer and treatment with hyperbaric chamber therapy.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>General Surgery</sub_title>
                <description>During the inpatient stay, 1 participant had gallbladder surgery, 1 participant had a suprapubic catheter inserted, 1 participant had flap surgery for a decubitus ulcer, and 1 participant had an intrathecal baclofen pump inserted.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Hypocalcemia (low blood calcium) occurred in 1 participant and resolved within one week without any specific therapy instituted.</description>
                <counts group_id="E1" events="8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting was noted in 6 of the 8 participants in the zoledronic acid arm.</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Febrile Reaction</sub_title>
                <description>In the zoledronic acid arm, 4 participants experienced low grade fevers while 2 participants experienced moderate to severe fevers.</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <description>All participants in the zoledronic acid arm experienced mild to severe lethargy (drowsiness).</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>All subjects in the zoledronic acid arm experienced mild to severe myalgia (muscle pain).</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The clinical trial was not randomized, it had a relatively small sample size, and 5 participants received high-dose corticosteroids in an attempt to preserve neurologic function upon that could have had a profound adverse effect on the skeleton.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William A. Bauman, M.D.</name_or_title>
      <organization>James J. Peters VA Medical Center</organization>
      <phone>718-584-9000 ext 5428</phone>
      <email>william.bauman@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

